Skip to main content

Advertisement

Table 1 Baseline characteristics of the study patients

From: Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial

Characteristic Group P-value
Control group (N = 80) N-acetylcysteine group (N = 81)
Gender
 Female, n (%) 52 (65.0) 45 (55.6) 0.144
Age, years 56.56 ± 12.41 53.28 ± 11.90 0.089
Body mass index, kg/m2 22.16 ± 4.22 22.72 ± 3.57 0.362
Ex-smoker, n (%) 8 (10.0) 6 (7.4) 0.381
mMRC score(≥2) 48 (60.0) 45 (55.6) 0.341
CAT score 19.55 ± 7.26 19.15 ± 7.12 0.723
24-h sputum volume, mL 28.84 ± 40.94 29.74 ± 41.35 0.890
Etiology of bronchiectasis    0.179
 Postinfectious 38 (47.5) 30 (37.0)  
 Idiopathic 42 (52.5) 51 (63.0)  
HRCT grade, n (%) 0.194
 1 28 (35.0) 27 (33.3)
 2 41 (51.2) 34 (42.0)
 3 11 (13.8) 20 (24.7)
Number of lesion lobes, n (%) 0.822
 1 lobe 15 (18.8) 18 (22.2)
 2–3 lobes 47 (58.8) 44 (54.3)
 4–6 lobes 18 (22.5) 19 (23.5)
Cystiform bronchiectasis, n (%) 33 (41.2) 44 (54.3) 0.097
Pseudomonas aeruginosa positive, n (%) 20 (25.0) 27 (33.3) 0.245
Medications, n (%)
 Inhaled corticosteroids and long-acting β-agonist 45 (56.2) 56 (69.1) 0.091
 Inhaled short-acting β-agonist 20 (25.0) 15 (18.5) 0.391
 Inhaled anticholinergics 22 (27.5) 24 (29.6) 0.765
 Inhaled corticosteroids 17 (21.2) 11 (13.6) 0.199
Prednisone 2 (2.5) 3 (3.8) 1.000
Theophylline 6 (7.5) 4 (5.0) 0.746
Pulmonary function
 FVC, L 2.42 ± 0.94 2.32 ± 0.74 0.483
 FEV1, L 1.56 ± 0.81 1.62 ± 0.73 0.629
 Predicted FEV1, % 63.63 ± 26.28 60.23 ± 27.32 0.451
 FEV1/FVC, % 64.39 ± 14.63 67.44 ± 16.49 0.226
 Inspiratory capacity, L 1.77 ± 0.70 1.88 ± 0.81 0.368
ESR, mm/h 25.39 ± 19.86 27.53 ± 24.07 0.540
CRP, mg/dL 16.99 ± 21.26 13.37 ± 17.12 0.246
Number of exacerbations in the last year 2 (2–3) 2 (2–3) 0.713
Bronchiectasis Severity Index 8.00 ± 4.27 8.43 ± 4.68 0.548
  1. Data are n (%) or mean ± SD or median (IQR). Abbreviations: mMRC modified Medical Research Council, CAT chronic obstructive pulmonary disease assessment test, HRCT high resolution computed tomography, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, ESR erythrocyte sedimentation rate, CRP C-reactive protein